头条新闻
-
2年前
Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update
marketscreener.com
-
2年前
Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update
finance.yahoo.com
-
2年前
LOS40 Music Awards Santander 2023: ¿Dónde verlos?
los40.cl
-
2年前
Hermoso Trains With Spain For First Time After Rubiales Kiss Scandal
barrons.com
-
2年前
Why Revolution Medicines Stock Is Crashing Today
nasdaq.com
-
2年前
Why Revolution Medicines Stock Is Crashing Today
fool.com
-
2年前
Why Revolution Medicines Stock Is Crashing Today
finance.yahoo.com
-
2年前
Johnson & Johnson : Phase 3 MARIPOSA-2 Study Shows RYBREVANT® (amivantamab-vmjw) Plus Chemotherapy Given with or without Lazertinib Reduced Risk of Disease Progression or Death by 56% and 52% in Patients with EGFR-Mutated NSCLC who Progressed on or after Osimertinib
marketscreener.com
-
2年前
Johnson & Johnson : Landmark Phase 3 MARIPOSA Study Shows RYBREVANT® (amivantamab-vmjw) Plus Lazertinib Resulted in 30 Percent Reduction in Risk of Disease Progression or Death Compared to Osimertinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer
marketscreener.com